Fujifilm (OTCMKTS:FUJIY) Shares Gap Up - Time to Buy?

Key Points

• Fujifilm Holdings Corp. shares gapped up from $11.93 to $12.48 before the market opened on Wednesday, indicating a potentially bullish trend.
• Analysts have dropped Fujifilm's rating from "buy" to "hold," suggesting cautious sentiment among market watchers.
• The company reported a net margin of 7.93% for the last quarter, with earnings per share meeting the consensus estimate of $0.15.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $11.93, but opened at $12.48. Fujifilm shares last traded at $12.48, with a volume of 345 shares changing hands.

Analysts Set New Price Targets

Separately, Wall Street Zen downgraded shares of Fujifilm from a "buy" rating to a "hold" rating in a report on Friday, May 23rd.

Fujifilm Stock Performance

The stock has a market cap of $30.08 billion, a P/E ratio of 10.89, a PEG ratio of 2.26 and a beta of 0.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.48 and a quick ratio of 0.92. The firm's 50-day moving average price is $11.03 and its 200-day moving average price is $10.57.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The technology company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Fujifilm had a net margin of 7.93% and a return on equity of 7.60%. The company had revenue of $5.08 billion for the quarter, compared to analysts' expectations of $760.41 billion. Sell-side analysts expect that Fujifilm Holdings Corp. will post 0.66 earnings per share for the current fiscal year.

About Fujifilm

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.